Catalyst Pharmaceuticals (CPRX) Shares Outstanding (Weighted Average) (2010 - 2026)

Catalyst Pharmaceuticals has reported Shares Outstanding (Weighted Average) for 17 years, with the latest figure at $122.3 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 0.64% year-over-year to $122.3 million; the trailing twelve-month figure through Mar 2026 stood at $122.3 million (up 0.64% YoY), and the FY2025 full-year result was $122.3 million, up 3.24% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $122.3 million, roughly flat from $122.3 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $122.6 million in Q3 2025, with the low at $102.8 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $112.9 million across 5 years, with a median of $116.8 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Weighted Average) declined 0.99% — and 2024, when it advanced 11.6%.
• Catalyst Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $103.4 million in 2022, then climbed by 2.81% to $106.3 million in 2023, then rose by 11.46% to $118.5 million in 2024, then increased by 3.24% to $122.3 million in 2025, then fell by 0.03% to $122.3 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $122.3 million (Q1 2026), $122.3 million (Q4 2025), and $122.6 million (Q3 2025), per Business Quant data.